No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TNDM240719P47500
- 5.20
- +3.05+141.86%
15min DelayClose Jul 18 16:00 ET
5.20High1.20Low
1.20Open2.15Pre Close16 Volume131 Open Interest47.50Strike Price4.24KTurnover177.37%IV0.75%PremiumJul 19, 2024Expiry Date4.88Intrinsic Value100Multiplier1DDays to Expiry0.32Extrinsic Value100Contract SizeAmericanOptions Type-0.8470Delta0.0551Gamma8.20Leverage Ratio-0.3192Theta-0.0012Rho-6.94Eff Leverage0.0057Vega
Intraday
- 5D
- Daily
News
Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024
PDF VersionSAN DIEGO--(BUSINESS WIRE)--Jul. 11, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024
Glaukos Cut as Citi Reviews U.S. MedTechs
Citi Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $57
Citi analyst Joanne Wuensch maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and maintains the target price at $57.According to TipRanks data, the analyst has a success rate of 60.7% and
Understanding Tandem Diabetes Care: Joanne Wuensch's Investment Perspective
Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index surging around 200 points on Monday.Shares of Corning Incorporated (NYSE:GLW) rose sharply during Monday's session after the company increased its sec
Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60
Stifel analyst Mathew Blackman maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and maintains the target price at $60.According to TipRanks data, the analyst has a success rate of 47.9% an
Comments
$Tandem Diabetes Care(TNDM.US$
Just check call options. they are expensive
However, stock price moves only 5-10% with no news. Something is going on behind the scene?!
Just check call options. they are expensive
However, stock price moves only 5-10% with no news. Something is going on behind the scene?!
2
Despite losses and negative cash flow, the company's US$178.2m balance sheet allows for at least two years of growth spending. However, the stock is seen as risky due to these financial conditions.
1
Tandem Diabetes Care's share price rise sparks hope, but turnarounds can be risky. The gap between revenue and share price growth could warrant further investigation. Last year's performance suggests unresolved issues, as it underperformed the annualised 10% loss over the past five years.
The stock is undervalued, indicating a potential buy opportunity. The company's positive future outlook and expected earnings increase aren't fully reflected in the current share price. Consider the company's financial health as well.
Despite the good rate of top-line growth at Tandem Diabetes Care, the severe share price drop indicates the company's losses might be larger than expected. Given the stock's past poor performance, there may be unresolved challenges the company is facing.
Read more